Synergistic apoptotic effect of Doxil® and aminolevulinic acid-based photodynamic therapy on human breast adenocarcinoma cells

Photodiagnosis and Photodynamic Therapy

Volumn 11, Issue 2, 2014, Pages 227-238

  Zakaria, Soad ^a   Gamal Eldeen, Amira M ^b   El Daly, Sherien M ^b   Saleh, Samira ^c  

^a 6 October Governorate   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

5 Aminolevulinic acid; Apoptosis; Breast cancer; Death receptors; Protoporphyrin IX

Indexed keywords

ALKALINE PHOSPHATASE; AMINOLEVULINIC ACID; CASPASE 3; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DNA; DOXORUBICIN; HISTONE DEACETYLASE; LIPID PEROXIDE; MALONALDEHYDE; PROTOPORPHYRIN; SINGLET OXYGEN; VASCULOTROPIN; ANTINEOPLASTIC ANTIBIOTIC; DEATH RECEPTOR; MACROGOL DERIVATIVE; RADIOSENSITIZING AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CELL DEATH; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CELL SURVIVAL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADENOCARCINOMA; AMINOLEVULINIC ACID; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MCF-7 CELLS; POLYETHYLENE GLYCOLS; RADIATION-SENSITIZING AGENTS; RECEPTORS, DEATH DOMAIN; TREATMENT OUTCOME;

EID: 84901603862     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2014.03.001     Document Type: Article

References (65)

1. Yang Y., Wang H. Perspectives of nanotechnology in minimally invasive therapy of breast cancer. J Healthc Eng 2013, 4(January):67-86.
2. Shirasu N., Nam S.O., Kuroki M. Tumor-targeted photodynamic therapy. Anticancer Res 2013, 33(July):2823-2831.
3. Allison R.R., Sibata C., Downie G.H., Cuenca R.E. Photodynamic therapy of the intact breast. Photodiagn Photodyn Ther 2006, 1(September (3)):139-146.
4. Milla Sanabria L., Rodríguez M.E., Cogno I.S., Rumie Vittar N.B., Pansa M.F., Lamberti M.J., et al. Direct and indirect photodynamic therapy effects on the cellular and molecular components of the tumor microenvironment. Biochim Biophys Acta 2013, 1835(January):36-45.
5. Atif M., Firdous S., Khurshid a., Noreen L., Zaidi S.S.Z., Ikram M. In vitro study of 5-aminolevulinic acid-based photodynamic therapy for apoptosis in human cervical HeLa cell line. Laser Phys Lett 2009, 6(December):886-891.
6. Allison R.R., Sibata C.H. Oncologic photodynamic therapy photosensitizers: a clinical review. Photodiagn Photodyn Ther 2010, 7(June):61-75.
7. Nokes B., Apel M., Jones C., Brown G., Lang J.E. Aminolevulinic acid (ALA): photodynamic detection and potential therapeutic applications. J Surg Res 2013, 181(May):262-271.
8. Weiss A., den Bergh H., Van, Griffioen A.W., Nowak-Sliwinska P. Angiogenesis inhibition for the improvement of photodynamic therapy: the revival of a promising idea. Biochim Biophys Acta 2012, 1826(August):53-70.
9. Roland T., Skeel S.N.K. Handbook of Cancer Chemotherapy 2011, Lippincott Williams & Wilkins, PA, USA. 8th ed.
10. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56(June):185-229.
11. Vandecruys E., Mondelaers V., De Wolf D., Benoit Y., Suys B. Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood. J Cancer Surviv 2012, 6(March):95-101.
12. Patel N.R., Pattni B.S., Abouzeid A.H., Torchilin V.P. Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev 2013, 10.1016/j.addr.2013.08.004.
13. Gabizon A., Shmeeda H., Grenader T. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy. Eur J Pharm Sci 2012, 45(March):388-398.
14. ®-the first FDA-approved nano-drug: lessons learned. J Control Release 2012, 160(June):117-134.
15. Hau P., Fabel K., Baumgart U., Rümmele P., Grauer O., Bock A., et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 2004, 100(March):1199-1207.
16. Anders C.K., Adamo B., Karginova O., Deal A.M., Rawal S., Darr D., et al. Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. PLoS ONE 2013, 8(January):e61359.
17. Gill S.E., Savage K., Wysham W.Z., Blackhurst D.W., Winter W.E., Puls L.E. Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: is it necessary?. Gynecol Oncol 2013, 129(June):544-547.
18. Rahman A.M., Yusuf S.W., Ewer M.S. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomed 2007, 2(January):567-583.
19. Bartal A., Mátrai Z., SzÛcs A., Liszkay G. Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy. Magy Onkol 2011, 55(June):91-98.
20. Snyder J.W., Greco W.R., Bellnier D.A., Vaughan L., Henderson B.W. Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer Res 2003, 63(23):8126-8131.
21. Ortel B., Chen N., Brissette J., Dotto G.P., Maytin E., Hasan T. Differentiation-specific increase in ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes. Br J Cancer 1998, 77(June (11)):1744-1751.
22. Tietz N.W., Rinker A.D., Shaw L.M. IFCC methods for the measurement of catalytic concentration of enzymes: Part 5. IFCC method for alkaline phosphatase (orthophosphoric-monoester phosphohydrolase, alkaline optimum, EC 3.1.3.1). J Clin Chem Clin Biochem 1983, 21(November (11)):731-748.
23. Giuliano M., Lauricella M., Vassallo E., Carabillò M., Vento R., Tesoriere G. Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors. Invest Ophthalmol Vis Sci 1998, 39(July (8)):1300-1311.
24. Gohel A., McCarthy M.B., Gronowicz G. Estrogen prevents glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro. Endocrinology 1999, 140(November (11)):5339-5347.
25. Messmer U.K., Reed U.K., Brüne B: Bcl-2 protects macrophages from nitric oxide-induced apoptosis. J Biol Chem 1996, 271(August (33)):20192-20197.
26. Burton K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 1956, 62(Febraury (2)):315-323.
27. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985, 150(October (1)):76-85.
28. Gamal-Eldeen A.M., El-Daly S.M., Borai I.H., Wafay H., Abdel-Ghaffar a.A.-R.B. Photodynamic therapeutic effect of indocyanine green entrapped in polymeric nanoparticles and their anti-EGFR-conjugate in skin cancer in CD1 mice. Photodiagn Photodyn Ther 2013, (April):1-14.
29. Talaat R.M. Soluble angiogenesis factors in sera of Egyptian patients with hepatitis C virus infection: correlation with disease severity. Viral Immunol 2010, 23(2):151-157.
30. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979, 95(June (2)):351-358.
31. Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011, 61(4):250-281.
32. Tsai T., Hong R.-L., Tsai J.-C., Lou P.-J., Ling I.-F., Chen C.-T. Effect of 5-aminolevulinic acid-mediated photodynamic therapy on MCF-7 and MCF-7/ADR cells. Lasers Surg Med 2004, 34(Janury (1)):62-72.
33. Scott L., Gibson, My Lien Nguyen, James J., Havens, Ayana Barbarin R.H. Relationship of δ-aminolevulinic acid-induced protoporphyrin IX levels to mitochondrial content in neoplastic cells in vitro. Biochem Biophys Res Commun 1999, 265(2):315-321.
34. Li Q., Wang X., Zhang K., Li X., Liu Q., Wang P. DNA damage and cell cycle arrest induced by protoporphyrin IX in Sarcoma 180 cells. Cell Physiol Biochem 2013, 32(January):778-788.
35. Millon S.R., Ostrander J.H., Yazdanfar S., Brown J.Q., Bender J.E., Rajeha A., et al. Preferential accumulation of 5-aminolevulinic acid-induced protoporphyrin IX in breast cancer: a comprehensive study on six breast cell lines with varying phenotypes. J Biomed Opt 2010, 15(January (1)):018002.
36. Seynhaeve A.L.B., Dicheva B.M., Hoving S., Koning G., Ten Hagen aT.L.M. Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: evaluated by in vitro/in vivo live cell imaging. J Control Release 2013, 172(September):330-340.
37. Wang J., Goh B., Lu W., Zhang Q., Chang A., Liu X.Y., et al. In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol Pharm Bull 2005, 28(May (5)):822-828.
38. Chen Q., Krol A., Wright A., Needham D., Dewhirst M.W., Yuan F. Tumor microvascular permeability is a key determinant for antivascular effects of doxorubicin encapsulated in a temperature sensitive liposome. Int J Hyperthermia 2008, 24(September):475-482.
39. Lee V.H.L., Ghandehari H., Maeda H., Nakamura H., Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 2013, 65(1):71-79.
40. Postiglione I., Chiaviello A., Palumbo G. Enhancing photodynamyc therapy efficacy by combination therapy: dated, current and oncoming strategies. Cancers (Basel) 2011, 9(June (3)):2597-2629.
41. Schleich K., Lavrik I.N. Mathematical modeling of apoptosis. Cell Commun Signal 2013, 11(January):44.
42. Estaquier J., Vallette F., Vayssiere J.-L., Mignotte B. The mitochondrial pathways of apoptosis. Adv Exp Med Biol 2012, 942(January):157-183.
43. Klein G. Cancer, apoptosis, and nonimmune surveillance. Cell Death Differ 2004, 11:13-17.
44. Toné S., Sugimoto K., Tanda K., Suda T., Uehira K., Kanouchi H., et al. Three distinct stages of apoptotic nuclear condensation revealed by time-lapse imaging, biochemical and electron microscopy analysis of cell-free apoptosis. Exp Cell Res 2007, 313(October (16)):3635-3644.
45. Savill J., Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000, 407:784-788.
46. Fukuhara H., Inoue K., Kurabayashi A., Furihata M., Fujita H., Utsumi K., et al. The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer. Photodiagn Photodyn Ther 2013, 10(4):399-409.
47. Chen X., Zhao P., Chen F., Li L., Luo R. Effect and mechanism of 5-aminolevulinic acid-mediated photodynamic therapy in esophageal cancer. Lasers Med Sci 2011, 26(January):69-78.
48. Diez B., Ernst G., Teijo M.J., Batlle A., Hajos S., Fukuda H. Combined chemotherapy and ALA-based photodynamic therapy in leukemic murine cells. Leuk Res 2012, 36(September):1179-1184.
49. Wang S., Konorev E.A., Kotamraju S., Joseph J., Kalivendi S., Kalyanaraman B: Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways. J Biol Chem 2004, 279(June):25535-25543.
50. Stassi G., De Maria R. Autoimmune thyroid disease: new models of cell death in autoimmunity. Nat Rev Immunol 2002, 2(March):195-204.
51. Singh T.R., Shankar S., Chen X., Asim M., Srivastava R.K. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 2003, 63(September):5390-5400.
52. Turner A., Li L.-C., Pilli T., Qian L., Wiley E.L., Setty S., et al. MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells. PLoS ONE 2013, 8(January):e56817.
53. Buytaert E., Dewaele M., Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta 2007, 1776(September):86-107.
54. Matthews G.M., Newbold A., Johnstone R.W. Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. Adv Cancer Res 2012, 116(January):165-197.
55. Fulda S. Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis. Exp Cell Res 2012, July (318):1208-1212.
56. Grabarska A., Dmoszyńska-Graniczka M., Nowosadzka E., Stepulak A. Histone deacetylase inhibitors-molecular mechanisms of actions and clinical applications. Postepy Hig Med Dosw 2013, 67(January):722-735.
57. Ma J., Wang Y., Zheng D., Wei M., Xu H., Peng T. Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways. Cardiovasc Res 2013, 97(January):77-87.
58. Kim J., Freeman MR: JNK/SAPK mediates doxorubicin-induced differentiation and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 2003, 79(June):321-328.
59. Maytin E.V., Honari G., Khachemoune A., Taylor C.R., Ortel B., Pogue B.W., et al. Vitamin D combined with aminolevulinate (ALA)-mediated photodynamic therapy (PDT) for human psoriasis: a proof-of-principle study. Isr J Chem 2012, 52(September):767-775.
60. Anand S., Honari G., Hasan T., Elson P., Maytin E.V. Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin Cancer Res 2009, 15(May):3333-3343.
61. Ortel B., Sharlin D., O'Donnell D., Sinha a K., Maytin E.V., Hasan T. Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells. Br J Cancer 2002, November (87):1321-1327.
62. Mohamed Ali E., Manal Shetab M.A.E.M. Elevated serum and tissue VEGF associated with poor outcome in breast cancer patients. Alexandria J Med 2011, 47(September (3)):217-224.
63. Inoue K., Fukuhara H., Kurabayashi A., Furihata M., Tsuda M., Nagakawa K., et al. Photodynamic therapy involves an antiangiogenic mechanism and is enhanced by ferrochelatase inhibitor in urothelial carcinoma. Cancer Sci 2013, 104(June (6)):765-772.
64. Lisnjak I.O., Kutsenok V.V., Polyschuk L.Z., Gorobets O.B., Gamaleia N.F. Effect of photodynamic therapy on tumor angiogenesis and metastasis in mice bearing Lewis lung carcinoma. Exp Oncol 2005, 27(December):333-335.
65. Tong Z., Miao P., Liu T., Jia Y., Liu X. Enhanced antitumor effects of BPD-MA-mediated photodynamic therapy combined with adriamycin on breast cancer in mice. Acta Pharmacol Sin 2012, October (33):1319-1324.